<DOC>
	<DOCNO>NCT02890992</DOCNO>
	<brief_summary>Primary Objective : To evaluate effect alirocumab low-density lipoprotein cholesterol ( LDL-C ) level 8 week treatment heterozygous familial hypercholesterolemia ( heFH ) patient age 8 17 year , LDL-C ≥130 mg/dL ( 3.37 mmol/L ) optimal stable daily dose statin therapy +/- lipid modifying therapy ( LMTs ) stable dose non-statin LMTs case intolerance statin least 4 week prior screen period . Secondary Objectives : - To evaluate safety tolerability alirocumab . - To evaluate pharmacokinetics profile alirocumab . - To evaluate effect alirocumab lipid parameter .</brief_summary>
	<brief_title>An 8-Week Dose-Finding Study Evaluate Efficacy Safety Alirocumab Children Adolescents With Heterozygous Familial Hypercholesterolemia</brief_title>
	<detailed_description>A study duration approximately 16-23 week ( screen period : 6 ( +1 ) week , open-label dose find treatment period : 8 week , follow period : 6-8 week ) . Optional extension period : maximum 2 year depend date study entry .</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hyperlipoproteinemia Type II</mesh_term>
	<mesh_term>Cholestyramine Resin</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<mesh_term>Fenofibrate</mesh_term>
	<mesh_term>Niacin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
	<criteria>Inclusion criterion : Children adolescent male female patient age 8 17 year time sign informed consent . For Russia : Male female patient age ≥12 ≤17 year time sign informed consent . Patients diagnosis heterozygous familial hypercholesterolemia ( heFH ) genotyping clinical criterion . Patients treat optimal dose statin +/ LMT ( ) nonstatin LMT ( ) statin intolerant stable dose least 4 week prior screen lipid sampling . Patients calculate LDLC great equal 130 mg/dL ( ≥3.37 mmol/L ) screen visit . Patients body weight great equal 25kg . Patients age 8 9 year Tanner stage 1 patient age 10 17 year least Tanner stage 2 development . A sign informed consent indicate parental permission without patient assent . Exclusion criterion : Patient secondary hyperlipidemia . Diagnosis homozygous familial hypercholesterolemia . Patient receive lipid apheresis treatment within 2 month prior screen period , plan receive study . Known history type 1 type 2 diabetes mellitus . Known history thyroid disease . Known history hypertension . Fasting triglyceride &gt; 350 mg/dL ( 3.95 mmol/L ) . Severe renal impairment ( ie , estimate glomerular filtration rate [ eGFR ] &lt; 30 mL/min/1.73 m^2 . Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &gt; 2 x upper limit normal ( ULN ) . Creatinine phosphokinase ( CPK ) &gt; 3 x ULN . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>